GeneSight Pharmacogenomic Testing Guidelines

Introduction to GeneSight Coding

The American Medical Association recommends using specific molecular pathology or proprietary laboratory analysis (PLA) codes designated for GeneSight testing, as the coding landscape for molecular diagnostics has evolved significantly 1, 2, 3.

Molecular diagnostic tests, such as GeneSight, require specific CPT codes that account for the complexity of the testing, rather than generic procedure codes, according to the American Medical Association 2.
The current coding system has moved away from "stacked coding" toward comprehensive codes that capture the entire test, as recommended by the American Medical Association 3.
Inclusion of a code in the CPT manual does not automatically guarantee insurance coverage or reimbursement, and medical necessity must still be demonstrated, as stated by the American Medical Association 1.

All molecular tests, including GeneSight, must be supported with medical necessity using appropriate diagnostic codes (ICD-10), and specific documentation in the medical record is necessary to provide support for the test, as required by the American Medical Association 4, 5.
The billing physician must certify that services were personally furnished or supervised, which has implications for how the test interpretation is billed, according to the American Gastroenterological Association 6.

Coverage for pharmacogenomic testing, such as GeneSight, varies significantly between Medicare, Medicaid, and private insurers, with no uniform policy, as reported by the National Comprehensive Cancer Network 2, 3.
Medicare and private insurers evaluate whether the test provides more accurate diagnostic information and improves health outcomes before determining coverage, as stated by the National Comprehensive Cancer Network 2.
Pharmacogenomic tests, including GeneSight, may require prior authorization or may only be covered in specific clinical contexts, according to the National Comprehensive Cancer Network 2.

The American Medical Association advises against using generic laboratory codes or incorrect CPT codes, as this will result in claim denials and potential compliance issues 1, 6.
It is essential to verify the specific CPT or PLA code designated for GeneSight testing with the test manufacturer or current CPT manual, as recommended by the American Medical Association 1.
The American Gastroenterological Association warns against billing for services not actually performed or supervised, as this constitutes a false claim 6.
Checking with individual payers regarding their specific coverage policies for GeneSight testing before ordering is crucial, as policies vary widely, according to the National Comprehensive Cancer Network 2, 3.